This is a working overview of peptide hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-06 and is reviewed periodically as new material appears.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
mildest type of nerve injury sensory-motor problems present distal to the site of injury, due to a nerve signal conduction block intact endoneurium, perineurium, and the epineurium wallerian degeneration not present intact conduction in the distal and proximal segments, but no conduction across the injury full nerve conduction recovery, requiring days to weeks fibrillation potentials (FP) lacking, and positive sharp EMG waves.
Mathematical and computational models are essential for understanding the action potential, and offer predictions that may be tested against experimental data, providing a stringent test of a theory. The most important and accurate of the early neural models is the Hodgkin–Huxley model, which describes the action potential by a coupled set of four ordinary differential equations (ODEs). Although the Hodgkin–Huxley model may be a simplification with few limitations compared to the realistic nervous membrane as it exists in nature, its complexity has inspired several even-more-simplified models, such as the Morris–Lecar model and the FitzHugh–Nagumo model, both of which have only two coupled ODEs. The properties of the Hodgkin–Huxley and FitzHugh–Nagumo models and their relatives, such as the Bonhoeffer–Van der Pol model, have been well-studied within mathematics, computation and electronics. However the simple models of generator potential and action potential fail to accurately reproduce the near threshold neural spike rate and spike shape, specifically for the mechanoreceptors like the Pacinian corpuscle. More modern research has focused on larger and more integrated systems; by joining action-potential models with models of other parts of the nervous system (such as dendrites and synapses), researchers can study neural computation and simple reflexes, such as escape reflexes and others controlled by central pattern generators.
Xi's first marriage was to Ke Lingling, the daughter of Ke Hua, China's ambassador to the United Kingdom in the early 1980s. They divorced within a few years. The two were said to fight "almost every day," and after the divorce, Ke moved to the UK. In 1987, Xi married famed folk singer Peng Liyuan. Xi and Peng were introduced by friends as many Chinese couples were in the 1980s. Peng had gained fame in the 1980s and remained far better known in China than Xi until the latter emerged as a likely successor in the late 2000s. The couple frequently lived apart due largely to their separate professional lives. Peng has played a much more visible role as China's "first lady" compared to her predecessors; for example, Peng hosted U.S. First Lady Michelle Obama on her high-profile visit to China in March 2014. Xi and Peng have a daughter named Xi Mingze, who graduated from Harvard University in the spring of 2015. While at Harvard, she used a pseudonym and studied Psychology and English. Xi's family has a home in Jade Spring Hill, a garden and residential area in north-western Beijing run by the CMC. In June 2012, Bloomberg News reported that members of Xi's extended family including his sister Qi Qiaoqiao have substantial business interests, although there was no evidence he had intervened to assist them. The Bloomberg News website was blocked in mainland China in response to the article about his family's wealth and the sales of Bloomberg Terminals in China slowed, while access to the files of Qinchuan Dadi, which was Qi's investment vehicle, was shut down.
AMPylators have been shown to be comparable to kinases due to their ATP hydrolysis activity and reversible transfer of the metabolite to a hydroxyl side chain of the protein substrate. However, AMPylation catalyse a nucleophilic attack on the α-phosphate group, while kinase in the phosphorylation reaction targets γ-phosphate. The nucleophilic attack of AMPylation leads to release Pyrophosphate and the AMP-modified protein are the products of the AMPylation reaction.
=== Dosage === Adult: Each tablet contains flupentixol 0.5 mg and melitracen 10 mg. The usual adult dose is one tablet in the morning and one at midday; in severe cases the morning dose may be increased to two tablets. The maximum recommended dose is four tablets per day. Elderly: The usual starting dose is one tablet in the morning; in severe cases, one tablet may also be given at midday.
Sources: en.wikipedia.org
=== December === 1 December: Prime Minister Christopher Luxon and Local Government Minister Simon Watts announce that the Government will introduce legislation to limit annual rates increases by local governments will be limited to between 2 and 4% The Professional Association for Transgender Health Aotearoa (PATHA) files a legal injunction to stop the incoming ban on new puberty blocker prescriptions, which is expected to come into force on 19 December. 3 December: A tornado causes power outages to 200 properties in the Manawatū-Whanganui region and damages several caravans at a Lake Dudding motor camp, wounding one person. Five new cases of measles are confirmed, bringing the total number of cases nationwide in the 2025 outbreak to 27. 4 December: Woolworths admits to one charge of violating the Food Act 2014 in relation to a rodent infestation at its South Dunedin store in February 2024. Former Te Pāti Māori MP Mariameno Kapa-Kingi files an interim injunction at the Wellington High Court challenging her expulsion from the party. The Post Primary Teachers' Association agrees to accept the Government's pay offer providing two pay rises totalling 4.6 percent over the next two years. Swedish multinational furniture retailer IKEA opens its first New Zealand store in Mount Wellington, Auckland. Thousands including Prime Minister Christopher Luxon attend the opening ceremony. 5 December: Member of Parliament Mariameno Kapa-Kingi is reinstated as a member of Te Pāti Māori by an interim Wellington High Court ruling.
=== Injection valve === The injection valve is a motorized valve which links the mixer and sample loop to the column. Typically the valve has three positions for loading the sample loop, for injecting the sample from the loop into the column, and for connecting the pumps directly to the waste line to wash them or change buffer solutions. The injection valve has a sample loading port through which the sample can be loaded into the injection loop, usually from a hypodermic syringe using a Luer-lock connection.
Terrestrial radiation is the ubiquitous radiation on Earth caused by radionuclides in the ground that were formed billions of years ago by stellar nucleosynthesis and have not yet decayed due to their long half-lives. Terrestrial radiation is caused by natural radionuclides that occur naturally in the Earth's soil, rocks, hydrosphere, and atmosphere. Natural radionuclides can be divided into cosmogenic and primordial nuclides. Cosmogenic nuclides do not contribute significantly to the terrestrial ambient radiation at the Earth's surface. The sources of terrestrial radiation are the natural radioactive nuclides found in the uppermost layers of the Earth, in the water and in the air. These include in particular
Parmotrema perlatum is globally widespread lichen found on all continents except Antarctica and predominantly in oceanic areas in Europe, primarily grows on bark and occasionally on siliceous rocks amongst mosses. While it is seeing an increase in the Netherlands due to global warming, it is critically endangered in the Czech Republic, Slovakia, and Poland due to susceptibility to air pollution, and is listed as extinct in certain regional Red Data Books due to a lack of recent findings. In contrast, it has been increasing in sightings in the Netherlands, a phenomenon attributed to both global warming decreases in the levels or air pollution in recent decades. Its recent recurrence in Hungary, particularly on some unusual hosts (Catalpa bignonioides, Prunus serotina, and Robinia pseudoacacia) have been suggested as a possible consequence of "a recolonisation process, due to the improving air quality".
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.